HAL Allergy extends GMP contract manufacturing activities
Major step forward in progress towards becoming a key biotech service company
Netherlands-based HAL Allergy has succeeded in extending its GMP contract manufacturing activities for clinical batch supply of both recombinant and viral products. The Dutch inspectorate granted the permit extension after inspection of the operational activities in the BSL2 cleanrooms and development laboratory in June 2012.
In 2009 the company opened its state-of-the-art production facility at the Bio Science Park in Leiden. The business was subsequently expanded into contract manufacturing to offer the competences of its pharmaceutical specialists to customers in need of reliable GMP services. During the start-up of this new business, the co-operation with the contract research organisation Batavia Bioservices for process know-how and Yxion for engineering were crucial.
‘The fact that the Dutch authorities extended our GMP permit is a big step forward in our goal of becoming a key biotech service company,’ said Harry Flore, ceo of HAL Allergy. ‘Modern production and laboratory facilities and more than 50 years’ experience in vaccine production will be key asset in partnerships with our customers.’
